Recherche Translationnelle en Oncogénèse Génito-Urinaire


The INSERM U955 Equipe/team 07 is a strong association of clinicians, oncologists, pathologists, biochemists and basic researchers in a dedicated environment that allows high scientific level facilities working on prostate and bladder cancers.


The goal is to determine the most relevant molecular events to define the molecular risk factors associated with therapy success and resistance and to identify new therapeutic targets.


During the past 5 years, the group worked on identifying biomarkers to try to reduce overdiagnosis and personalized therapeutic approaches in prostate cancer such as urine PCA3, serum testosterone, betaTUBIII, protocadherin PC, androgen receptor and telomerase instability and molecular pathways PI3K/Akt, Wnt (Wnt / β-catenin).

An inhibitor of nucleophosmin N6L was also evaluated. Hormonal environment was also evaluated in Caucasian and Caribbean patients and highlighted that estrone and estrone sulfate levels were correlated with aggression.

The team identified FSH receptor on the surface of endothelial cells that correlates with tumor behavior. In bladder cancer, FGFR3 mutations correlated with superficial cancers was validated and loss of CDKN2A expression was found to be associated with aggressiveness.

Two programs for Excellence in bladder cancer were initiated: (1) CIT on the association between cancer and the presence of aggressive T2 MRES (Regional Multiple Epigenetic Silencing) phenotype and on the characterization of a subset of T2 with an addiction to EGFR pathway and (2) the FP7 program involving DECaNBio with Spain in 1070 patients with bladder cancer to explore by SRM the aggressiveness and recurrence of low-grade cancer markers.

The next projects on prostate cancer are to continue to investigate biomarkers of lethal prostate cancer using high-throughput microarray technologies (PAIR Prostate), to validate new prostate cancer treatments such as mdv3100, orteronel or abiraterone, to find molecular pathways involved in resistance on preclinical models, to study regulations of cancer cell proliferation and invasion by Heparin-affin regulatory growth factor (HARP) and to determine hormonal profiles of prostate cancer patients.

For bladder cancer, our group will develop the molecular taxonomy of bladder cancer and continue to validate new prognostic factors.

Voir aussi : Service d’Urologie, Hôpital Henri Mondor


Publications récentes

François CM, Petit F, Giton F, Gougeon A, Ravel C, Magre S, Cohen-Tannoudji J, Guigon CJ. A novel action of follicle-stimulating hormone in the ovary promotes estradiol production without inducing excessive follicular growth before puberty

Sci Rep. 2017 Apr 11;7:46222.

Peyronnet B, Khene ZE, Pradère B, Seisen T, Verhoest G, Masson-Lecomte A, Grassano Y, Roumiguié M, Beauval JB, Baumert H, Droupy S, Doumerc N, Bernhard JC, Vaessen C, Bruyère F, de la Taille A, Rouprêt M, Bensalah K. Off-Clamp versus On-Clamp Robotic Partial Nephrectomy: A Multicenter Match-Paired Case-Control Study

Study. Urol Int. 2017 Apr 6. doi: 10.1159/000471772

Beauval JB, Cabarrou B, Gandaglia G, Patard PM, Ouzzane A, de la Taille A, Soulié M, Briganti A, Ploussard G, Rozet F, Roumiguié M. External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients

Prostate. 2017 Jun;77(8):928-933

Mathieu R, Moschini M, Beyer B, Gust KM, Seisen T, Briganti A, Karakiewicz P, Seitz C, Salomon L, de la Taille A, Rouprêt M, Graefen M, Shariat SF. Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):197-202

Corbineau S, Lassalle B, Givelet M, Souissi-Sarahoui I, Firlej V, Romeo PH, Allemand I, Riou L, Fouchet P. Spermatogonial stem cells and progenitors are refractory to reprogramming to pluripotency by the transcription factors Oct3/4, c-Myc, Sox2 and Klf4

Oncotarget. 2017 Feb 7;8(6):10050-10063

Lebacle C, Roudot-Thoraval F, Moktefi A, Bouanane M, De La Taille A, Salomon L. Integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy

World J Urol. 2016 Dec 19. doi: 10.1007/s00345-016-1981-5

Beauval JB, Ploussard G, Cabarrou B, Roumiguié M, Ouzzane A, Gas J, Goujon A, Marcq G, Mathieu R, Vincendeau S, Cathelineau X, Mongiat-Artus P, Salomon L, Soulié M, Méjean A, de La Taille A, Rouprêt M, Rozet F; Committee of Cancerology of the Association of French Urology.. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy

World J Urol. 2016 Dec 16. [Epub ahead of print] PubMed PMID: 27987030

Rousseau B, Kempf E, Desamericq G, Boissier E, Chaubet-Houdu M, Joly C, Saldana C, Boussion H, Neuzillet C, Macquin-Mavier I, Oudard S, Salomon L, de la Taille A, Tournigand C. First-line antiangiogenics for metastatic renal cellcarcinoma: A systematic review and network meta-analysis

Crit Rev Oncol Hematol. 2016 Nov;107:44-53

Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort

Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52

Beauval JB, Roumiguié M, Filleron T, Benoit T, de la Taille A, Malavaud B, Salomon L, Soulié M, Ploussard G. Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer

BMC Urol. 2016 Jun 8;16(1):26